In Brief: Dynagen NicErase-SL
Dynagen NicErase-SL: Clinical development of lobeline sublingual tablet is discontinued after combined results of a 750-subject multicenter Phase III trial did not yield statistically significant results. NicErase continues to be developed by Nastech Pharmaceutical for a nasally administered formulation. Dynagen is in discussions with Lohmann Therapie Systeme over development of transdermal and transbuccal patch formulations of NicErase...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth